Characteristics of new users of statins in the period 1991–2004 in the PHARMO population F.J.A. Penning-van Beest, et al. European Heart Journal 2007;28:154–159.

Slides:

Advertisements

Similar presentations

Time line of data collection in the Nurses’ Health Study, 1988 to 2000 A. Heather Eliassen et al, Arch Intern Med. 2005; 165:

Advertisements

Description of Each Study in the Cross Trial Safety Analysis Solomon SD, et al. Circulation 2008 [Epub Mar 31]

Coronary heart disease (CHD) event rates in secondary prevention and acute coronary syndrome trials A. Kumar, C.P. Cannon. Arch Med Sci 2007;3:S115-S125.

David N. Juurlink, et al. CMAJ 2009;180: (7) [Epub]

What do hospitals do for patient outcomes? 30 day mortality after heart attack Future of healthcare in Europe 13 May 2011.

New concepts and guidelines in the management of LDL-c and CV Risk: Need for early intervention Prof. Ulf Landmesser University Hospital Zürich Switzerland.

Trial profile Fox K et al. Lancet 2008;372:

Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia James Shepherd, M.D., Stuart M. Cobbe, M.D., Ian Ford, Ph.D., Christopher.

1 EPI235: Epi Methods in HSR May 3, 2007 L10 Outcomes and Effectiveness Research 4: HMO/Network (Dr. Schneeweiss) Methodologic issues in benchmarking physician.

Efficacy and safety of angiotensin receptor blockers: a meta-analysis of randomized trials Elgendy IY et al. Am J Hypertens. 2014; doi:10,1093/ajh/hpu209.

COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)

Baseline Characteristics of Individuals From the General Population by Quartiles of Triglyceride Levels a Børge G. Nordestgaard, et al. JAMA 2007;298:

ELIGIBILITY: MRC/BHF Heart Protection Study Increased risk of CHD death due to prior disease: Myocardial infarction or other coronary heart disease; Occlusive.

Laura Mucci, Pharm.D. Candidate Mercer University 2012 Preceptor: Dr. Rahimi February 2012.

Ho PM, et al. JAMA 2009;301: Baseline Characteristics of Patients Taking Clopidogrel After Hospital Discharge a Ho PM, et al. JAMA 2009;301:

Lancet 373: , 2009 Baseline Characteristics of Participants and Study Design of Clinical Trials to Compare Intensive glucose- lowering versus.

Demographic Characteristics of the Study Population - Part I Jenny N.Poynter et al N Engl J Med 2005;352:

SPARCL – Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Jim McMorran Coventry GP GP with Specialist Interest in Diabetes and.

David J. Graham et al. JAMA, 2004; 292: 2585 Description of Inception Cohorts for Patients Using Statin and Fibrate Drug Therapy.

Achievement of cholesterol targets and prescribing of higher-cost statins: a cross-sectional study in general practice by Robert Fleetcroft, Peter Schofield,

ANTIPLATELET TREATMENT IN PATIENTS WHO HAVE AN ISCHEMIC STROKE WHILE TAKING ASPIRIN Konstantinos Tziomalos, Stella D. Bouziana, Marianna Spanou, Stavroula.

From Knowledge to Practice Translation A Multidisciplinary Intervention to Reduce 30 day Heart Failure Readmissions.

Baseline Patient Characteristics Bart A.N. Verhoeven, et al. Stroke 2006;37:

Shalev V, et al. Arch Intern Med 2009; 169:

Rosuvastatin 10 mg n=2514 Placebo n= to 4 weeks Randomization 6weeks3 monthly Closing date 20 May 2007 Eligibility Optimal HF treatment instituted.

ELIGIBILITY: MRC/BHF Heart Protection Study Increased risk of CHD death due to prior disease: Myocardial infarction or other coronary heart disease; Occlusive.

Presentation Title R3 이지영 / 김 수 중교 수 님. Introduction Lowering LDL cholesterol levels with statins : Reduce the risk of cardiovascular disease Vascular.

Flow Diagram of the Trial Selection Process Jeffrey S. Berger et al, JAMA. 2006;295:

Multivariate associations* between selected covariates and statin use Jawahar L. Mehta, et al. Am J Cardiol 2006;98:923–928.

Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated.

Discontinuation of medication after nonfatal event: MI

Flow of Individuals Through the Vitamin E and Vitamin C Components of the Physicians’ Health Study II Howard D. Sesso et al. JAMA 2008;300:

Trial profile SAS denotes the Simvastatin in Aortic Stenosis Study

Figure 1 Patient flow chart.

Major recommendation for statin therapy for ASCVD prevention

Baseline Characteristics of Women and Men in Whom Coronary Heart Disease Developed during Follow-up and Matched Controls - A Jennifer K. Pai et al. N.

ELIGIBILITY: MRC/BHF Heart Protection Study

Baseline characteristics of patients

Distribution of lifespan for men initiating preventative therapy (with a risk reduction of 30%) at the age of 50, with national average blood pressure.

Hippisley-Cox J, Coupland C. BMJ 2010;340:c2197

How to Teach it?.

Selmer R, et al. Br J Clin Pharmacol 2009;67:355-62

P2Y12 blockade versus placebo; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial infarction and.

Flow chart of the study population according to thienopyridines used in the FAST-MI registry in patients with STEMI and NSTEMI. FAST-MI, French Registry.

by John Robson, Sally Hull, Rohini Mathur, and Kambiz Boomla

Classification of statins/dosages according to the attainable

Baseline Characteristics

Potential mechanisms whereby statins may reduce the risk of stroke

On Statin Treatment to Prevent Sepsis in Dialysis Patients

Characteristics of elderly patients prescribed statins after acute myocardial infarction (AMI) in Quebec, Ontario and British Columbia - Part I Zheng.

Nat. Rev. Cardiol. doi: /nrcardio

Estimated 5-year rate of a first major vascular event (MVE), major coronary event (MCE),or vascular death in univariate and multivariate risk subgroups.

Flow diagram for exclusions of trials identified RCT indicates randomized controlled trial Hulten E, et al. Arch Intern Med 2006;166:

Ongoing statin therapy at hospitalization for acute myocardial infarction. Learnings for general practitioners. Ghena Shabana Specialist in Family Medicine.

Baseline Demographic Characteristics of Adults With Diagnosed Heart Failure and Eligible to Receive Lipid-Lowering Therapy Alan S. Go, et al.

Participation in Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial Hisao Ogawa et al. JAMA 2008;300:

Baseline Characteristics of the Patients – Part I

Characteristics of included studies

An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61

Associations between atmospheric chemistry transport model pollution concentrations at lags 0, 1 and 2 and myocardial infarction (% change in risk per.

EMPA-REG OUTCOME: Cumulative incidence of the primary outcome

Comparison of outcomes in patients with versus patients without diabetes; primary outcome event rate (CV death, non-fatal MI and non-fatal CVA) as a percentage.

An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61

Association between statin dose and 1-year admission to hospital for cardiovascular events in older Ontario residents living in long-term care facilities.

Evolution of prospectively planned primary end points in completed CVOTs of antihyperglycemic treatments for type 2 diabetes, listed in order of year of.

Prasugrel versus clopidogrel; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial infarction and.

Prevalence of acute myocardial infarction (AMI) or other cardiovascular events (CVEs) according to the presence of acute respiratory failure (ARF) and.

Prevalence of acute myocardial infarction (AMI) or other cardiovascular events (CVEs) according to a) Pneumonia Severity Index (PSI) risk classes and b)

Prasugrel and ticagrelor versus clopidogrel; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial.

Proportions of the social isolation—AMI and stroke excess risk mediated by biological, behavioural, socioeconomic and health-related factors. Proportions.

Presentation transcript:

Characteristics of new users of statins in the period 1991–2004 in the PHARMO population F.J.A. Penning-van Beest, et al. European Heart Journal 2007;28:154–159

Characteristics of new users of statins, by persistence and average dose of statin use during the first 2 years of treatment F.J.A. Penning-van Beest, et al. European Heart Journal 2007;28:154–159

Effect of persistence and dose of statin use during the first 2 years of treatment on risk of hospitalization for myocardial infarction, by type of prevention F.J.A. Penning-van Beest, et al. European Heart Journal 2007;28:154–159

Equipotency and percentage reduction in total cholesterol according to the different types and doses of statins F.J.A. Penning-van Beest, et al. European Heart Journal 2007;28:154–159

Type, dose, and equipotency of the statin last prescribed before the start of outcome follow-up in 2-year persistent users, by average equipotent dose during the first 2 years of treatment F.J.A. Penning-van Beest, et al. European Heart Journal 2007;28:154–159